Jennison Associates LLC Aerie Pharmaceuticals Inc Transaction History

Jennison Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 07, 2020	SELL	$17.72 - $25.1 $555,238 - $786,483	-31,334 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$18.41 - $28.0 $14.2 Million - $21.5 Million	-769,474 Reduced 96.09%	31,334 $602,000
Q2 2019 Aug 06, 2019	SELL	$28.97 - $48.21 $15.8 Million - $26.2 Million	-544,191 Reduced 40.46%	800,808 $0
Q1 2019 May 10, 2019	BUY	$36.32 - $49.25 $5.87 Million - $7.96 Million	161,538 Added 13.65%	1,344,999 $63.9 Million
Q4 2018 Feb 06, 2019	SELL	$33.0 - $60.04 $6.69 Million - $12.2 Million	-202,750 Reduced 14.63%	1,183,461 $42.7 Million
Q3 2018 Nov 08, 2018	BUY	$56.15 - $73.9 $4.29 Million - $5.65 Million	76,390 Added 5.83%	1,386,211 $85.3 Million
Q2 2018 Aug 02, 2018	SELL	$47.85 - $70.45 $9.18 Million - $13.5 Million	-191,774 Reduced 12.77%	1,309,821 $88.5 Million
Q1 2018 Apr 20, 2018	BUY	$51.15 - $61.0 $5.54 Million - $6.6 Million	108,222 Added 7.77%	1,501,595 $81.5 Million
Q4 2017 Jan 25, 2018	SELL	$50.85 - $65.1 $24.7 Million - $31.7 Million	-486,240 Reduced 25.87%	1,393,373 $83.3 Million
Q3 2017 Nov 03, 2017	BUY	$48.6 - $60.1 $91.3 Million - $113 Million	1,879,613	1,879,613 $91.3 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.